Our research group is focused on developing low-cost solutions to gene therapy in the eye so that the benefits of this powerful treatment may be available globally. The strategy is based on adapting mRNA technology to inherited eye diseases and numerous chronic retinal diseases. Our lab has been investigating approaches to combine the in vitro mRNA system with biomaterial-based systems as a patient-friendly therapy.